| Essential Acute Stroke Care in Low Resource Settings: a Pilot studY (NCT04157231) | The George Institute | 2027-12-30 |
| INTERACT4 Expansion - Validation Study (NCT07231315) | The George Institute | 2026-02-01 |
| PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury (NCT06819592) | The George Institute | 2025-10-30 |
| Optimised Treatment for Hypertension Trial (NCT06935760) | The George Institute | 2025-08-28 |
| FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage (NCT06409364) | The George Institute | 2025-08-13 |
| The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL (NCT06763055) | The George Institute | 2025-02-27 |
| Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial (NCT06352619) | The George Institute | 2024-10-11 |
| ACT-GLOBAL Adaptive Platform Trial for Stroke (NCT06352632) | The George Institute | 2024-09-26 |
| The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (NCT06058585) | The George Institute | 2024-09-04 |
| Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR) (NCT06559072) | The George Institute | 2024-09-01 |
| Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression (NCT06278779) | The George Institute | 2024-06-03 |
| Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis (NCT05752279) | The George Institute | 2024-03-14 |
| PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care (NCT05468203) | The George Institute | 2023-11-29 |
| Trial of Enhanced Neurostimulation for Anorexia (NCT05788042) | The George Institute | 2023-08-02 |
| The RAFT ECT Study (NCT05402657) | The George Institute | 2023-03-22 |
| SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes (NCT05345327) | The George Institute | 2023-01-01 |
| TESTING -ON Post-Trial ObservatioNal Cohort Study (NCT05434325) | The George Institute | 2022-12-07 |
| Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial (NCT05129722) | The George Institute | 2022-10-01 |
| SMART Health Pregnancy 2 - Intervention to Reduce Anaemia and Cardiometabolic Risk During Pregnancy and in the First Year Following Birth (NCT05752955) | The George Institute | 2022-06-06 |
| Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy (NCT04904536) | The George Institute | 2022-03-10 |
| Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS (NCT04494789) | The George Institute | 2021-02-11 |
| Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (NCT03969953) | The George Institute | 2021-01-18 |
| Preventing Adverse Cardiac Events in COPD (NCT03917914) | The George Institute | 2020-06-30 |
| Global Kidney Patient Trials Network (NCT04389827) | The George Institute | 2020-05-05 |
| Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study (NCT03785067) | The George Institute | 2020-02-27 |
| The Effects on Blood Pressure of Salt Substitute Among Adults With Hypertension in India (NCT03909659) | The George Institute | 2019-11-25 |
| Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study (NCT03783754) | The George Institute | 2018-08-09 |
| Beta-Lactam InfusioN Group Study (NCT03213990) | The George Institute | 2018-03-26 |
| Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (NCT02699645) | The George Institute | 2017-09-28 |
| Plasma-Lyte 148® versUs Saline Study (NCT02721654) | The George Institute | 2017-09-01 |